Duloxetine Capsule, Delayed Release
Product Images NDC 70518-3287

20 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-3287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Structure (Duloxetine Structure)
Chemical structure diagram of Duloxetine hydrochloride, showing the molecular arrangement including a thiophene ring and a naphthyl group linked to an amine hydrochloride moiety.*
FDA Label Image

Figure1 (Duloxetine Fig1)

Figure1 (Duloxetine Fig1)
A Kaplan-Meier survival curve comparing time from randomization to relapse in days for patients treated with Duloxetine versus placebo. The y-axis shows the proportion of patients with relapse, and the x-axis shows the time in days. Duloxetine shows a lower proportion of patients with relapse over time compared to placebo.*
FDA Label Image

Figure2 (Duloxetine Fig2)

Figure2 (Duloxetine Fig2)
A line graph titled to show the proportion of patients with relapse over time from randomization in days. It compares two treatments, Duloxetine and placebo, showing Duloxetine with a lower relapse proportion curve than placebo across approximately 0 to 250 days.*
FDA Label Image

Figure3 (Duloxetine Fig3)

Figure3 (Duloxetine Fig3)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved ranging from 0 to 70%.*
FDA Label Image

Figure4 (Duloxetine Fig4)

Figure4 (Duloxetine Fig4)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg administered twice daily (BID), once daily (QD), and placebo, illustrating that Duloxetine (both dosing regimens) resulted in higher patient improvement percentages than placebo across various levels of pain improvement.*
FDA Label Image

Figure5 (Duloxetine Fig5)

Figure5 (Duloxetine Fig5)
Line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Three lines compare Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends of patient improvement across varying percentages of pain reduction.*
FDA Label Image

Figure6 (Duloxetine Fig6)

Figure6 (Duloxetine Fig6)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine at different doses (120 mg, 60 mg, and 20 mg once daily) with placebo. The y-axis shows the percentage of patients improved, ranging from 0 to 100%, and the x-axis represents percent improvement in pain from baseline, from greater than 0 to 100 percent.*
FDA Label Image

Figure7 (Duloxetine Fig7)

Figure7 (Duloxetine Fig7)
A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline. It shows two lines: one for Duloxetine 60 mg once daily and another for placebo, illustrating higher patient improvement with Duloxetine across various pain improvement percentages.*
FDA Label Image

Figure8 (Duloxetine Fig8)

Figure8 (Duloxetine Fig8)
A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The y-axis shows percentage of patients improved from 0% to 100%, and the x-axis shows percent improvement in pain from baseline ranging from >0% to 100%. Duloxetine consistently shows higher patient improvement percentages than placebo across the measured values.*
FDA Label Image

Figure9 (Duloxetine Fig9)

Figure9 (Duloxetine Fig9)
A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline (BOCF) ranging from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two lines represent placebo and Duloxetine, with Duloxetine generally showing higher improvement percentages across the pain improvement spectrum.*
FDA Label Image

Figure10 (Duloxetine Fig10)

Figure10 (Duloxetine Fig10)
A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows the percent improvement in pain, with data points connected by lines for each treatment group.*
FDA Label Image

Mm1 (Duloxetine 30mg 70518 3287 00)

Mm1 (Duloxetine 30mg 70518 3287 00)
Duloxetine Capsule delayed-release 30 mg, 60 count capsules in a blister or bottle packaging label. Label shows the NDC number 70518-3287-00 with repackaging information by RemedyRepack Inc., Indiana, PA. Manufactured by Ajanta Pharma Ltd., India. Storage instructions and dosage reference to insert are visible.*
FDA Label Image

Mm2 (Duloxetine 30mg 70518 3287 01)

Mm2 (Duloxetine 30mg 70518 3287 01)
Duloxetine 30 mg delayed-release capsules carton label showing quantity of 30 capsules. The label indicates the product is repackaged by RemedyRepack Inc., with NDC 70518-3287-01. The manufacturer listed is Ajanta Pharma Ltd., Paithan, India. Storage temperature instructions and a QR code are also visible.*
FDA Label Image

Mm3 (Duloxetine 30mg 70518 3287 02)

Mm3 (Duloxetine 30mg 70518 3287 02)
Duloxetine Capsule delayed-release 30 mg label for a 90-capsule package. The label includes the NDC 70518-3287-02 and indicates repackaging by RemedyRepack Inc., Indiana, PA. It advises usual dosage to be seen in the insert and provides storage instructions at 20-25°C with permitted excursions. Manufacturer is Ajanta Pharma Ltd., Paithan, India.*
FDA Label Image

Mm4 (Duloxetine 30mg 70518 3287 03)

Mm4 (Duloxetine 30mg 70518 3287 03)
Duloxetine Capsule delayed-release 30 mg label showing quantity of 50 capsules per box, repackaged by RemedyRepack Inc., Indiana, PA. The label includes storage instructions and manufacturer details as Ajanta Pharma Ltd., India. The NDC number 70518-3287-03 is visible.*
FDA Label Image

Mm5 (Duloxetine 30mg 70518 3287 04)

Mm5 (Duloxetine 30mg 70518 3287 04)
Duloxetine delayed-release capsule 30 mg packaging label showing a quantity of 1 capsule. The label includes the NDC number 70518-3287-04, storage instructions, repackager RemedyRepack Inc., and manufacturer Ajanta Pharma Ltd. in India. The label states "RX ONLY" and advises to see the insert for usual dosage.*
FDA Label Image

Mm6 (Duloxetine 30mg 70518 3287 05)

Mm6 (Duloxetine 30mg 70518 3287 05)
Duloxetine 30 mg delayed-release capsules, repackaged by RemedyRepack Inc. The label indicates a quantity of 50 capsules per box, with NDC 70518-3287-05. The manufacturer is Ajanta Pharma Ltd., Paithan, India. Storage instructions specify keeping the product at 20-25°C with permitted excursions and to keep out of reach of children. The label includes a QR code and states 'RX ONLY.'*
FDA Label Image

Mm7 (Duloxetine 30mg 70518 3287 06)

Mm7 (Duloxetine 30mg 70518 3287 06)
Duloxetine Capsule delayed-release 30 mg oral dosage form, single capsule quantity. Label includes NDC 70518-3287-06, manufacturer Ajanta Pharma Ltd., India. Packaging states storage instructions, lot number and expiration fields, and is repackaged by RemedyRepack Inc., Indiana, PA. Contains a QR code and dosage direction note to see insert.*
FDA Label Image

Mm8 (Duloxetine 30mg 70518 3287 07)

Mm8 (Duloxetine 30mg 70518 3287 07)
Duloxetine Capsule delayed-release 30 mg label showing a package quantity of 50 capsules per box. The NDC number 70518-3287-07 is visible. The label includes storage instructions, manufacturer information (Ajanta Pharma Ltd., India), repackager details (RemedyRepack Inc., Indiana, PA), and a QR code. It is marked RX only with dosage directions to see the insert.*
FDA Label Image

Mm9 (Duloxetine 30mg 70518 3287 08)

Mm9 (Duloxetine 30mg 70518 3287 08)
Duloxetine Capsule delayed-release 30 mg, single capsule pack labeled by RemedyRepack Inc. The label includes storage instructions, manufacturer Ajanta Pharma Ltd., and states Rx only and usual dosage see insert. The label is primarily white with purple accents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.